Literature DB >> 16479168

Alternative splicing increases complexity of stem cell transcriptome.

Ihor R Lemischka1, Moshe Pritsker.   

Abstract

Development of highly anticipated stem cell-based therapies requires a detailed understanding of mechanisms regulating biological properties of these cells. Comprehensive identification of all biological molecules produced in stem cells is an important step toward this goal. During the past several years, microarray studies have essentially identified genes that are transcriptionally activated in various embryonic and adult stem cell populations. However, the extent of post-transcriptional modifications within the stem cell transcriptome remained undetermined. Recently, we presented evidence that thousands of genes expressed in hematopoietic and embryonic stem cells undergo alternative splicing. Using combined computational and experimental analyses, we found that the frequency of alternative splicing is especially high in tissue-specific genes, as compared to ubiquitous genes. Our results also indicate that negative regulation of constitutively active splicing sites can be a prevalent mode for generation of splicing variants, and that alternative splicing is generally not conserved between orthologous genes in human and mouse. Here, we discuss the implications of our findings for stem cell biology, and present possible approaches toward genome-wide identification and characterization of splice variants.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16479168     DOI: 10.4161/cc.5.4.2424

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  9 in total

1.  Detection of low-abundant novel transcripts in mouse hematopoietic stem cells.

Authors:  Hyeng-Soo Kim; Junmo Hwang; Young-Hun Kim; Seonggon Kim; Jae-Woong Lee; Hyung-Sik Kang; Kil Soo Kim; Ji-Hong Ha; Jin Woong Chung; Kyu-Tae Chang; Zae Young Ryoo; Sanggyu Lee
Journal:  Mol Genet Genomics       Date:  2009-07-08       Impact factor: 3.291

Review 2.  Hematopoietic stem and progenitor cell signaling in the niche.

Authors:  Stephanie N Hurwitz; Seul K Jung; Peter Kurre
Journal:  Leukemia       Date:  2020-10-19       Impact factor: 11.528

3.  Human ESC/iPSC-based "Omics" and Bioinformatics for Translational Research.

Authors:  Gerd Müller; Kirill V Tarasov; Rebekah L Gundry; Kenneth R Boheler
Journal:  Drug Discov Today Dis Models       Date:  2012

4.  Alternative splicing switching in stem cell lineages.

Authors:  Iouri Chepelev; Xin Chen
Journal:  Front Biol (Beijing)       Date:  2013-02-01

5.  Switched alternative splicing of oncogene CoAA during embryonal carcinoma stem cell differentiation.

Authors:  Zheqiong Yang; Yang Sui; Shiqin Xiong; Sean S Liour; Andrew C Phillips; Lan Ko
Journal:  Nucleic Acids Res       Date:  2007-03-01       Impact factor: 16.971

6.  Increasing the relative expression of endogenous non-coding Steroid Receptor RNA Activator (SRA) in human breast cancer cells using modified oligonucleotides.

Authors:  Charlton Cooper; Jimin Guo; Yi Yan; Shilpa Chooniedass-Kothari; Florent Hube; Mohammad K Hamedani; Leigh C Murphy; Yvonne Myal; Etienne Leygue
Journal:  Nucleic Acids Res       Date:  2009-05-29       Impact factor: 16.971

7.  Restricted expression of Epstein-Barr virus latent genes in murine B cells derived from embryonic stem cells.

Authors:  Magdalena Zychlinska; Heidrun Herrmann; Ursula Zimber-Strobl; Wolfgang Hammerschmidt
Journal:  PLoS One       Date:  2008-04-16       Impact factor: 3.240

8.  Fine-tuning of microRNA-mediated repression of mRNA by splicing-regulated and highly repressive microRNA recognition element.

Authors:  Cheng-Tao Wu; Chien-Ying Chiou; Ho-Chen Chiu; Ueng-Cheng Yang
Journal:  BMC Genomics       Date:  2013-07-03       Impact factor: 3.969

9.  RRP1B is a metastasis modifier that regulates the expression of alternative mRNA isoforms through interactions with SRSF1.

Authors:  M Lee; A M Dworkin; D Gildea; N S Trivedi; G B Moorhead; N P S Crawford
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.